The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study

SIMPLE SUMMARY: This study collected data from patients with cutaneous melanoma with mutation in the B-RAF gene who were treated with the combination of dabrafenib and trametinib in 34 Italian hospitals in every-day clinical practice. The aim was to understand how these drugs modify the progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Vecchio, Michele, Chiarion Sileni, Vanna, Quaglino, Pietro, Rinaldi, Gaetana, Minisini, Alessandro, Troiani, Teresa, Consoli, Francesca, Sponghini, Andrea, Banzi, Maria, Morelli, Maria Francesca, Palleschi, Dario, Rossi, Ernesto, Marconcini, Riccardo, Depenni, Roberta, Carnevale-Schianca, Fabrizio, Marcon, Ilaria, Queirolo, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093702/
https://www.ncbi.nlm.nih.gov/pubmed/37046641
http://dx.doi.org/10.3390/cancers15071980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093702/
https://www.ncbi.nlm.nih.gov/pubmed/37046641
http://dx.doi.org/10.3390/cancers15071980

Ejemplares similares